US Patents for PCT: WO2012/080471
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-001 | Sep 20, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS | |||
| Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-002 | Sep 20, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS | |||
| Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-003 | Sep 20, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS | |||
| Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-006 | Dec 9, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS | ||
| Novo | WEGOVY | semaglutide | TABLET;ORAL | 218316-003 | Dec 22, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION | |||
| Novo | WEGOVY | semaglutide | TABLET;ORAL | 218316-004 | Dec 22, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
